Search Results
You are looking at 1 - 1 of 1 items for
- Author: Adrian Herington x
- Refine by access: All content x
Institute of Health and Biomedical Innovation, Vancouver Prostate Centre, Departments of Medicine and Oncology, Australian Prostate Cancer Research Centre – Queensland, Princess Alexandra Hospital, Queensland University of Technology, Level 1, Building 1, 199 Ipswich Road, Brisbane, Queensland 4102, Australia
Search for other papers by Amy A Lubik in
Google Scholar
PubMed
Search for other papers by Jennifer H Gunter in
Google Scholar
PubMed
Search for other papers by Brett G Hollier in
Google Scholar
PubMed
Search for other papers by Susan Ettinger in
Google Scholar
PubMed
Search for other papers by Ladan Fazli in
Google Scholar
PubMed
Search for other papers by Nataly Stylianou in
Google Scholar
PubMed
Search for other papers by Stephen C Hendy in
Google Scholar
PubMed
Search for other papers by Hans H Adomat in
Google Scholar
PubMed
Search for other papers by Martin E Gleave in
Google Scholar
PubMed
Search for other papers by Michael Pollak in
Google Scholar
PubMed
Search for other papers by Adrian Herington in
Google Scholar
PubMed
Institute of Health and Biomedical Innovation, Vancouver Prostate Centre, Departments of Medicine and Oncology, Australian Prostate Cancer Research Centre – Queensland, Princess Alexandra Hospital, Queensland University of Technology, Level 1, Building 1, 199 Ipswich Road, Brisbane, Queensland 4102, Australia
Search for other papers by Colleen C Nelson in
Google Scholar
PubMed
IGF2 is a mitogenic foetal growth factor commonly over-expressed in cancers, including prostate cancer (PC). We recently demonstrated that insulin can activate de novo steroidogenesis in PC cells, a major pathway for reactivation of androgen pathways and PC progression. IGF2 can activate the IGF1 receptor (IGF1R) or insulin receptor (INSR) or hybrids of these two receptors. We therefore hypothesized that IGF2 may contribute to PC progression via de novo steroidogenesis. IGF2 mRNA but not IGF2 receptor mRNA expression was increased in patient samples during progression to castrate-resistant PC as was immunoreactivity to INSR and IGF1R antibodies. Treatment of androgen receptor (AR)-positive PC cell lines LNCaP and 22RV1 with IGF2 for 48 h resulted in increased expression of steroidogenic enzyme mRNA and protein, including steroid acute regulatory protein (StAR), cytochrome p450 family member (CYP)17A1, aldo–keto reductase family member (AKR)1C3 and hydroxysteroid dehydrogenase (HSD)17B3. IGF2 treatment resulted in increased steady state steroid levels and increased de novo steroidogenesis resulting in AR activation as demonstrated by PSA mRNA induction. Inhibition of the IGF1R/INSR signalling axis attenuated the effects of IGF2 on steroid hormone synthesis. We present a potential mechanism for prostatic IGF2 contributing to PC progression by inducing steroidogenesis and that IGF2 signalling and related pathways present attractive targets for PC therapy.